Efficacy and safety of Tumour necrosis factor inhibitors, Interleukin-17 inhibitors, and Janus kinase inhibitors in patients with non-radiographic axial spondyloarthritis: A systematic review and network meta-analysis.

IF 2.5 4区 医学 Q3 ALLERGY
Dan Li, Xinhui Zhang, Yunfei Tian, Jing Zhang, Xiaojuan Zhao, Menghao Li, Yonghong Zhao, Xiuju Liu
{"title":"Efficacy and safety of Tumour necrosis factor inhibitors, Interleukin-17 inhibitors, and Janus kinase inhibitors in patients with non-radiographic axial spondyloarthritis: A systematic review and network meta-analysis.","authors":"Dan Li, Xinhui Zhang, Yunfei Tian, Jing Zhang, Xiaojuan Zhao, Menghao Li, Yonghong Zhao, Xiuju Liu","doi":"10.1159/000542744","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>To systematically assess the efficacy and safety of tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i) and Janus kinase inhibitors (JAKi) in patients with non-radiographic axial spondyloarthritis (nr-axSpA).</p><p><strong>Methods: </strong>A systematic literature search was conducted in Pubmed, Embase, Web of Science and the Cochrane Register of Clinical Trials to find randomized controlled trials (RCTs) in patients with nr-axSpA published until June 2023, by two reviewers independently. Data extraction was carried out by two independent investigators. Stata 17.0 software and Review Manager 5.3 software were used to perform the data analysis. The results for binary and continuous variables were expressed as the values of odds ratio (OR) and mean difference (MD) and their 95% confidence interval (CI), respectively.</p><p><strong>Results: </strong>A total of 10 RCTs involving 2,418 participants were included in the analysis. The efficacy rankings were: certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W) > CZP 400 mg every 4 weeks (Q4W) > golimumab (GOL) > bimekizumab (BKZ) > adalimumab (ADA) > upadacitinib (UPA) > etanercept (ETN) > brodalumab (BRO) > ixekizumab (IXE) > secukinumab (SEC) 150 mg no loading (NL) > SEC 150 mg loading dose(LD) > placebo (PBO) for Assessment of SpondyloArthritis international Society response criteria for 40% improvement (ASAS40); GOL > CZP 400 mg Q4W> BKZ > ADA > UPA > CZP 200 mg Q2W > ETN > BRO > SEC 150 mg NL > SEC 150 mg LD > PBO for Assessment of SpondyloArthritis international Society response criteria for 20% improvement (ASAS20). Except for BRO, all treatments resulted in a significant improvement in ASAS40 compared with PBO. In terms of safety, the ranking was: GOL > ADA > PBO > UPA > SEC 150 mg NL > BKZ > IXE > SEC 150 mg LD > ETN > CZP 200 mg Q2W for adverse events (AE). There was no statistical difference in serious adverse events (SAE) among all drugs compared to PBO.</p><p><strong>Conclusions: </strong>Most TNFi could be more effective than JAKi and IL-17i. The safety of the therapies is generally good. However, the efficacy and safety of TNFi/IL-17i/JAKi remains to be further analyzed in studies with larger sample size and longer follow-up times.</p><p><strong>Trial registration: </strong>This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), with a registration number of CRD42023423725.</p>","PeriodicalId":13652,"journal":{"name":"International Archives of Allergy and Immunology","volume":" ","pages":"1-26"},"PeriodicalIF":2.5000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Archives of Allergy and Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000542744","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: To systematically assess the efficacy and safety of tumour necrosis factor inhibitors (TNFi), interleukin-17 inhibitors (IL-17i) and Janus kinase inhibitors (JAKi) in patients with non-radiographic axial spondyloarthritis (nr-axSpA).

Methods: A systematic literature search was conducted in Pubmed, Embase, Web of Science and the Cochrane Register of Clinical Trials to find randomized controlled trials (RCTs) in patients with nr-axSpA published until June 2023, by two reviewers independently. Data extraction was carried out by two independent investigators. Stata 17.0 software and Review Manager 5.3 software were used to perform the data analysis. The results for binary and continuous variables were expressed as the values of odds ratio (OR) and mean difference (MD) and their 95% confidence interval (CI), respectively.

Results: A total of 10 RCTs involving 2,418 participants were included in the analysis. The efficacy rankings were: certolizumab pegol (CZP) 200 mg every 2 weeks (Q2W) > CZP 400 mg every 4 weeks (Q4W) > golimumab (GOL) > bimekizumab (BKZ) > adalimumab (ADA) > upadacitinib (UPA) > etanercept (ETN) > brodalumab (BRO) > ixekizumab (IXE) > secukinumab (SEC) 150 mg no loading (NL) > SEC 150 mg loading dose(LD) > placebo (PBO) for Assessment of SpondyloArthritis international Society response criteria for 40% improvement (ASAS40); GOL > CZP 400 mg Q4W> BKZ > ADA > UPA > CZP 200 mg Q2W > ETN > BRO > SEC 150 mg NL > SEC 150 mg LD > PBO for Assessment of SpondyloArthritis international Society response criteria for 20% improvement (ASAS20). Except for BRO, all treatments resulted in a significant improvement in ASAS40 compared with PBO. In terms of safety, the ranking was: GOL > ADA > PBO > UPA > SEC 150 mg NL > BKZ > IXE > SEC 150 mg LD > ETN > CZP 200 mg Q2W for adverse events (AE). There was no statistical difference in serious adverse events (SAE) among all drugs compared to PBO.

Conclusions: Most TNFi could be more effective than JAKi and IL-17i. The safety of the therapies is generally good. However, the efficacy and safety of TNFi/IL-17i/JAKi remains to be further analyzed in studies with larger sample size and longer follow-up times.

Trial registration: This study has been registered in the International Prospective Register of Systematic Reviews (PROSPERO), with a registration number of CRD42023423725.

求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.60%
发文量
105
审稿时长
2 months
期刊介绍: ''International Archives of Allergy and Immunology'' provides a forum for basic and clinical research in modern molecular and cellular allergology and immunology. Appearing monthly, the journal publishes original work in the fields of allergy, immunopathology, immunogenetics, immunopharmacology, immunoendocrinology, tumor immunology, mucosal immunity, transplantation and immunology of infectious and connective tissue diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信